Connect with us

Technology

Medical Gas Blenders Market to Grow by USD 582 Million (2024-2028), Driven by Aging Population and Chronic Diseases, with AI Impacting Market Trends – Technavio

Published

on

NEW YORK, Dec. 11, 2024 /PRNewswire/ — Report on how AI is redefining market landscape – The global medical gas blenders market size is estimated to grow by USD 582 million from 2024-2028, according to Technavio. The market is estimated to grow at a CAGR of 5.42% during the forecast period. Growing geriatric population and rising prevalence of chronic diseases is driving market growth, with a trend towards increasing use of respiratory gas blenders in nicus. However, stringent regulations on design and manufacturing of medical gas blenders poses a challenge. Key market players include BioMed Devices, DEHAS Medical Systems GmbH, EKU Elektronik GmbH, ESAB Corp., Genstar Technologies Co. Inc., Guangdong Pigeon Medical Apparatus Co. Ltd., Halma Plc, HVS Oliver Hornla GmbH and Co. KG, Inspiration Healthcare Group Plc., MCQ Instruments, medin Medical Innovations GmbH, Ningbo David Medical Device Co. Ltd., Precision Medical Inc., S S Technomed P Ltd., Scanatron Technics AG, SHANGHAI AMCAREMED TECHNOLOGY Co. Ltd., TG Eakin Ltd., Weyer GmbH, WITT Gasetechnik GmbH and Co KG, and Zhengzhou Dison Instrument And Meter Co. Ltd..

AI-Powered Market Evolution Insights. Our comprehensive market report ready with the latest trends, growth opportunities, and strategic analysis- View Free Sample Report PDF

Forecast period

2024-2028

Base Year

2023

Historic Data

2018 – 2022

Segment Covered

End-user (Hospitals, Ambulatory surgical centers, Pharmaceuticals, Homecare settings, and Academic and research institutions), Product (Dual flow and Tube flow), and Geography (North America, Europe, Asia, and Rest of World (ROW))

Region Covered

North America, Europe, Asia, and Rest of World (ROW)

Key companies profiled

BioMed Devices, DEHAS Medical Systems GmbH, EKU Elektronik GmbH, ESAB Corp., Genstar Technologies Co. Inc., Guangdong Pigeon Medical Apparatus Co. Ltd., Halma Plc, HVS Oliver Hornla GmbH and Co. KG, Inspiration Healthcare Group Plc., MCQ Instruments, medin Medical Innovations GmbH, Ningbo David Medical Device Co. Ltd., Precision Medical Inc., S S Technomed P Ltd., Scanatron Technics AG, SHANGHAI AMCAREMED TECHNOLOGY Co. Ltd., TG Eakin Ltd., Weyer GmbH, WITT Gasetechnik GmbH and Co KG, and Zhengzhou Dison Instrument And Meter Co. Ltd.

Key Market Trends Fueling Growth

The Medical Gas Blenders Market is experiencing significant growth due to the increasing number of surgical procedures, driven by diseases such as cancer in the elderly population. Anesthesia delivery machines require a precise flow of gases like oxygen and nitrous oxide for controlled anesthesia during surgery. Manual handling of gases is being replaced by automated handling and electronic control systems. The gas blending system, breathing system, ventilating system, and gas exhaust system are essential components of anesthetic devices. Oxygen, nitrous oxide, and other anesthesia gases are in high demand in hospitals and Ambulatory Surgical Centers. The VMR industry report provides forward-looking analysis and actionable data on gas flows, automated processing, and information management systems. Electronic gas mixing and gas monitoring ensure patient safety and respiratory monitoring. Self-inspection and data systems facilitate efficient gas source management. Outpatient surgeries, hernia operations, hip replacements, and knee replacements are common procedures that utilize medical gas blenders. Chronic conditions, heart surgeries, brain surgeries, lung surgeries, orthopaedic surgeries, gastrointestinal surgeries, inhalable anesthetics, intravenous anesthesia, and cosmetic procedures all require anesthetic devices. Emerging economies and the geriatric population’s adoption of these technologies are key growth drivers. Electric power is a critical factor in the functioning of these devices. The market pitches, business plans, presentations, and proposals highlight the importance of these trends in the medical industry. Sample VMR reports are available with discounts. 

The medical gas blenders market is witnessing significant growth due to the increasing demand for respiratory gas blenders in healthcare facilities. Neonates and infants, particularly those born prematurely, require additional oxygen to breathe properly after birth. The use of medical gas blenders ensures the delivery of precise oxygen mixtures to these patients, preventing potential brain damage or even death. Vendors, such as Ohio Medical, provide reliable and advanced gas blenders, including the NEO2 blend and low-flow models, designed for Neonatal Intensive Care Units (NICUs), ensuring accurate gas mixing for optimal patient care. 

Insights on how AI is driving innovation, efficiency, and market growth- Request Sample!

Market Challenges

The Medical Gas Blenders Market faces several challenges in the healthcare industry. Diseases such as lung cancer, breast cancer, and prostate cancer require various surgical procedures, leading to an increased demand for anesthesia delivery machines and controlled anesthesia gases like oxygen and nitrous oxide. Manual handling of gases and knob adjustments in anesthetic devices can lead to errors. Electronic control and automated handling are solutions, but cost and self-inspection requirements add complexity. The VMR industry report highlights the importance of gas source, gas blending system, breathing system, ventilating system, gas exhaust system, data system, and electronic gas mixing for efficient gas monitoring and respiratory monitoring. Adoption of automated processing for air/oxygen and melting gas is increasing in Ambulatory Surgical Centers, Hospitals, and OECD countries. Emerging economies, geriatric population, and outpatient surgeries present growth opportunities. Electric power reliability and cost are key considerations. The market pitches, business plans, presentations, and proposals must address these challenges and provide actionable data and forward-looking analysis. Types of cancer, surgical admissions, and chronic conditions like heart and brain surgeries, hernia operations, hip replacement, and knee replacement drive demand for anesthesia gases and anesthetic devices. Inhalable anesthetics and intravenous anesthesia are alternatives. Medical practitioners and cosmetic procedures also utilize medical gas blenders. Medical tourism is a growing trend.Medical gas blenders are essential devices used in healthcare settings to deliver oxygen and heliox therapy, as well as life support in Intensive Care Units (ICUs) and emergency situations. The design and manufacturing of these devices are subject to stringent regulations to ensure safety and effectiveness. In Europe, medical gas blenders must comply with the Medical Device Directive (MDD), Directive 2007/47/EC, and Council Directive 93/42/EEC. Additionally, the oxygen used in medical gas blenders must meet regulatory standards, such as those set by the American National Standards Institute (ANSI) Z86 in the US. The production, handling, manufacturing, control, and distribution of medicinal oxygen are subject to rigorous regulations to maintain quality and safety.

Insights into how AI is reshaping industries and driving growth- Download a Sample Report

Segment Overview

This medical gas blenders market report extensively covers market segmentation by

End-user 1.1 Hospitals1.2 Ambulatory surgical centers1.3 Pharmaceuticals1.4 Homecare settings1.5 Academic and research institutionsProduct 2.1 Dual flow2.2 Tube flowGeography 3.1 North America3.2 Europe3.3 Asia3.4 Rest of World (ROW)

1.1 Hospitals- The hospital segment led the global medical gas blenders market in 2023, driven by the increasing patient population and subsequent demand for medical gas blenders. These devices are essential for delivering precise oxygen concentrations and flows to patients with hypoxic conditions. Medical gas blenders play a vital role in hospital care by enabling healthcare professionals to administer oxygen safely and accurately. With patient safety being a top priority, medical gas blenders are indispensable tools for ensuring optimal oxygen level monitoring. Consequently, the growing need for medical gas blenders in hospitals will fuel market expansion throughout the forecast period.

Download complimentary Sample Report to gain insights into AI’s impact on market dynamics, emerging trends, and future opportunities- including forecast (2024-2028) and historic data (2018 – 2022) 

Research Analysis

The Medical Gas Blenders Market refers to the production and supply of devices used for blending and delivering anesthesia gases for surgical procedures. These gases, including oxygen and nitrous oxide, are essential for controlled anesthesia during surgery. Manual handling of gases using knobs on anesthesia delivery machines has evolved to electronic control and automated handling for improved precision and safety. Gas blending systems ensure accurate mixing of anesthesia gases from various gas sources. The breathing system delivers gases to the patient, while the ventilating system assists in breathing. Gas exhaust systems remove waste gases, and data systems monitor gas flow, oxygen levels, and patient vitals. Electronic gas mixing and gas monitoring ensure safe and efficient delivery of anesthesia gases. Regular self-inspection is crucial to maintain the functionality and safety of medical gas blenders.

Market Research Overview

The Medical Gas Blenders Market is a critical segment of the healthcare industry, supplying essential gases for various medical applications, including surgical procedures and anesthesia delivery. Diseases such as lung cancer, breast cancer, prostate cancer, and chronic conditions necessitate surgeries, leading to an increased demand for medical gases. Elderly populations in emerging economies and the growing number of outpatient surgeries in Ambulatory Surgical Centers and Hospitals are significant factors driving market growth. Medical Gas Blenders are used to blend and deliver anesthesia gases, including oxygen, nitrous oxide, and other anesthetic gases, in controlled quantities. These systems consist of a gas source, gas blending system, breathing system, ventilating system, gas exhaust system, data system, and electronic gas mixing with gas monitoring and respiratory monitoring. Manual and electronic control options are available, with automated handling and self-inspection features. The VMR Industry Report provides forward-looking analysis, actionable data, and pitches, business plans, presentations, and proposals for investors and industry professionals. The report covers gas flows, automated processing, air/oxygen, melting gas, and various types of surgeries, including hernia operations, hip replacements, knee replacements, heart surgeries, brain surgeries, lung surgeries, orthopaedic surgeries, gastrointestinal surgeries, inhalable anesthetics, intravenous anesthesia, and cosmetic procedures. The adoption of electronic control and automated handling in medical gas blenders is increasing due to their advantages over manual handling, including improved accuracy, safety, and efficiency. The market is expected to grow significantly due to the increasing number of surgical admissions, electric power usage, and the geriatric population’s rising healthcare needs. OECD statistics indicate that surgical procedures accounted for over 50% of all healthcare spending in 2019. In conclusion, the Medical Gas Blenders Market is a vital sector of the healthcare industry, providing essential gases for various medical applications, and its growth is driven by demographic and technological factors.

Table of Contents:

1 Executive Summary
2 Market Landscape
3 Market Sizing
4 Historic Market Size
5 Five Forces Analysis
6 Market Segmentation

End-userHospitalsAmbulatory Surgical CentersPharmaceuticalsHomecare SettingsAcademic And Research InstitutionsProductDual FlowTube FlowGeographyNorth AmericaEuropeAsiaRest Of World (ROW)

7 Customer Landscape
8 Geographic Landscape
9 Drivers, Challenges, and Trends
10 Company Landscape
11 Company Analysis
12 Appendix

About Technavio

Technavio is a leading global technology research and advisory company. Their research and analysis focuses on emerging market trends and provides actionable insights to help businesses identify market opportunities and develop effective strategies to optimize their market positions.

With over 500 specialized analysts, Technavio’s report library consists of more than 17,000 reports and counting, covering 800 technologies, spanning across 50 countries. Their client base consists of enterprises of all sizes, including more than 100 Fortune 500 companies. This growing client base relies on Technavio’s comprehensive coverage, extensive research, and actionable market insights to identify opportunities in existing and potential markets and assess their competitive positions within changing market scenarios.

Contacts

Technavio Research
Jesse Maida
Media & Marketing Executive
US: +1 844 364 1100
UK: +44 203 893 3200
Email: media@technavio.com
Website: www.technavio.com/

View original content to download multimedia:https://www.prnewswire.com/news-releases/medical-gas-blenders-market-to-grow-by-usd-582-million-2024-2028-driven-by-aging-population-and-chronic-diseases-with-ai-impacting-market-trends—technavio-302327898.html

SOURCE Technavio

Continue Reading
Click to comment

Leave a Reply

Your email address will not be published. Required fields are marked *

Technology

51Talk Online Education Group to Report Third Quarter 2024 Financial Results on Friday, December 13, 2024

Published

on

By

Earnings Call Scheduled for 8:00 a.m. ET on December 13, 2024

SINGAPORE, Dec. 12, 2024 /PRNewswire/ — 51Talk Online Education Group (“51Talk”, or the “Company”) (NYSE American: COE), a global online education platform with core expertise in English education, today announced that it will report its unaudited financial results for the third quarter ended September 30, 2024 on Friday, December 13, 2024, before the open of U.S. markets.

The Company’s management will host an earnings conference call at 8:00 a.m. U.S. Eastern Time on December 13, 2024 (9:00p.m. Singapore/Beijing/Hong Kong time on December 13, 2024).

Dial-in details for the earnings conference call are as follows:

United States Toll:

1-888-346-8982

International:

1-412-902-4272

Singapore (toll free):

800-120-6157

Mainland China Toll:

4001-201203

Hong Kong Toll:

800-905945

Hong Kong-Local Toll:

852-301-84992

Participants should dial-in at least 5 minutes before the scheduled start time and ask to be connected to the call for “51Talk Online Education Group”.

Additionally, a live and archived webcast of the conference call will be available on the Company’s investor relations website at http://ir.51talk.com

A replay of the conference call will be accessible approximately one hour after the conclusion of the live call until December 20, 2024, by dialing the following telephone numbers:

United States Toll:

1-877-344-7529

International Toll:

1-412-317-0088 

Canada Toll:          

855-669-9658

Replay Access Code:

7344526

About 51Talk Online Education Group

51Talk Online Education Group (NYSE American: COE) is a global online education platform with core expertise in English education. The Company’s mission is to make quality education accessible and affordable. The Company’s online and mobile education platforms enable students to take live interactive English lessons on demand. The Company connects its students with a large pool of highly qualified teachers that it assembled using a shared economy approach, and employs student and teacher feedback and data analytics to deliver a personalized learning experience to its students. 

For more information, please visit http://ir.51talk.com

View original content:https://www.prnewswire.com/news-releases/51talk-online-education-group-to-report-third-quarter-2024-financial-results-on-friday-december-13-2024-302329810.html

SOURCE 51Talk Online Education Group

Continue Reading

Technology

WuXi Biologics Included in UNGC 20 Case Examples of Sustainable Development for 20 Years Collection

Published

on

By

Leading Green CRDMO Driven by Innovation for a Healthier FutureOffering End-to-end Green Biologics Solutions for the Entire Industry

SHANGHAI, Dec. 12, 2024 /PRNewswire/ — WuXi Biologics (“WuXi Bio”) (2269.HK), a leading global Contract Research, Development, and Manufacturing Organization (CRDMO), today announced that it has been included in the “20 Case Examples for 20 Years: Private Sector’s Sustainable Development in China” report initiated by the United Nations Global Compact. The company has been invited to UNGC global roadshow and has earned recognition for its effective and dedicated efforts to continue the advancement of green biologics solutions for a healthier future.

The year 2024 marks the 20th anniversary of the ESG (Environmental, Social and Governance) concept put forward by the UN Global Compact, and a series of ESG+20 celebration activities have been launched, with the “20 Case Examples for 20 Years: Private Sector’s Sustainable Development in China” report being a crucial component. The report aims to showcase best practices in ESG as a way to reveal contributions by companies successful in sustainability development transformation, as well as to share their innovative ideas and actions with the world.

Commenting on the report, Sanda Ojambo, Assistant Secretary-General of the United Nations Global Compact said, “On the occasion of the 20th anniversary of the introduction of the ESG (Environmental, Social and Governance) concept by the UN Global Compact, and the upcoming 25th anniversary of the UN Global Compact, our China Liaison Office has specially curated sustainability case studies from enterprises in China. These companies are distinctive in that, while pursuing economic development, they reflect their unique commitment to sustainable development. These cases not only highlight the economic efficiency, innovation and inclusivity of Chinese enterprises but showcase their efforts to balance social responsibility, environmental protection and economic growth. Through diverse sustainable development strategies, these enterprises promote the application of green technologies, responsible resource usage and community development, enriching the sustainability connotation of the Chinese economy and providing valuable experience and insights for global sustainable development goals.”

Dr. Chris Chen, CEO of WuXi Biologics and Chairman of its ESG Committee, commented, “We are honored to be included in the UN Global Compact report, which showcases our distinctive business model and the firm commitment to pursuing sustainable development. As a global leader in Green CRDMO, we continuously strive to deliver our own ESG excellence, while remaining dedicated to enabling global partners with end-to-end green biologics solutions driven by innovation — from green research,  green development, to green manufacturing. Going forward, we will keep pushing industry boundaries, jointly working with all stakeholders to promote responsible practices throughout the whole value chain.”

As a participant of the UN Global Compact, WuXi Biologics actively drives innovation and operational efficiency through green technology, and continuously makes contributions towards the United Nations Sustainable Development Goals. The company integrates green technology into its research, development, and manufacturing processes. In particular, it boasts of the proprietary universal bispecific antibody platform WuXiBody™ for green research; ultra-intensified fed-batch production platform WuXiUI™ and ultra-high productivity continuous processing platform WuXiUP™ for green development; and Single-Use Technology for green manufacturing. These technology platforms and processes can expedite timelines and increase productivity, while at the same time minimizing carbon footprint and end-of-life environmental impact through significant reductions in resource and energy consumption, and waste generation.

Over the past several years, WuXi Biologics has earned a number of recognitions for its significant progress in pursuing sustainable development. It was granted an AAA rating from MSCI ESG Ratings for two consecutive years; included in the DJSI World Index and Emerging Markets Index; awarded the distinguished Platinum Medal by EcoVadis; recognized as an Industry and Regional Top-Rated Company by Sustainalytics; named to the CDP Water Security “A list” and awarded an “A-” CDP Climate Change score; selected as a Constituent of the FTSE4Good Index Series; and included in the Hang Seng ESG 50 Index.

About the United Nations Global Compact Liaison Office in China
Since the establishment of the United Nations Global Compact Liaison Office in China in 2017, we have become increasingly convinced that Chinese enterprises and multinational companies operating in China are a positive force in advancing sustainable development for the planet at large.

As the world’s largest developing country, China not only boasts the most Fortune Global 500 companies (with 142 companies listed in 2023) but also hosts over 44 million small and medium-sized businesses. The sheer scale of China’s domestic economy, overseas investments and trade significantly influence the well-being of billions of people and the progress of sustainable development worldwide, underscoring the magnitude and importance of our collective work.

The United Nations Global Compact Liaison Office in China, with over 1,100 participants from various industries as of July 2024, tailors four major accelerator programmes for these participants: the Climate Ambition Accelerator (CAA), the Target Gender Equality (TGE), the SDG Innovation Accelerator for Young Professionals (SDGI) and the SDG Ambition Accelerator (SDGA).

Through programmes and events focused on climate change, zero-carbon transition, gender equality, supply chain resilience, sustainable business innovation, Sustainable Infrastructure for the Belt and Road Initiative to accelerate the SDGs, Sino-Africa Corporate Community Action Network on Sustainable Development and Global Development Initiative for SDGs Pilot Projects, we help to foster innovative and action-driven partnerships and support our Chinese participants to move towards a sustainable future along with partners from all over the world.

About WuXi Biologics
WuXi Biologics (stock code: 2269.HK) is a leading global Contract Research, Development and Manufacturing Organization (CRDMO) offering end-to-end solutions that enable partners to discover, develop and manufacture biologics – from concept to commercialization – for the benefit of patients worldwide.

With over 12,000 skilled employees in China, the United States, Ireland, Germany and Singapore, WuXi Biologics leverages its technologies and expertise to provide customers with efficient and cost-effective biologics discovery, development and manufacturing solutions. As of June 30, 2024, WuXi Biologics is supporting 742 integrated client projects, including 16 in commercial manufacturing (excluding COVID CMO and non-COVID dormant CMO projects).

WuXi Biologics views Environmental, Social, and Governance (ESG) responsibilities as an integral component of our ethos and business strategy, and we aim to become an ESG leader in the biologics CRDMO sector. Our facilities use next-generation biomanufacturing technologies and clean-energy sources. We have also established an ESG committee led by our CEO to steer the comprehensive ESG strategy and its implementation, enhancing our commitment to sustainability.

For more information about WuXi Biologics, please visit: www.wuxibiologics.com

Contacts
Media
PR@wuxibiologics.com 

Business
info@wuxibiologics.com 

View original content:https://www.prnewswire.com/news-releases/wuxi-biologics-included-in-ungc-20-case-examples-of-sustainable-development-for-20-years-collection-302329945.html

SOURCE WuXi Biologics

Continue Reading

Technology

EQUIDUCT WELCOMES IBROKER AS THE LATEST TRADING PARTICIPANT TO JOIN APEX

Published

on

By

MADRID, Dec. 12, 2024 /PRNewswire/ — Equiduct, the retail-focused pan-European exchange, announced today that iBroker Global Markets S.V. is the newest trading participant to join its Best Execution service, Apex.

iBroker is the leading online broker in listed derivatives in Spain, specializing in the retail segment. Now, with its incorporation into Equiduct and as part of the company’s new strategic plan, it is expanding its product offering to include European equities and ETFs.

iBroker and its clients are already leveraging Equiduct´s high quality market data products, which offers a real-time consolidated view of liquidity from twelve major European markets.

By joining Equiduct, iBroker and its retail investors’ client base, now have access to pan-European liquidity for over 1,900 stocks and ETF, joining over 7 million retail end clients that already benefit from the best-in class execution and market-data services provided by Equiduct.

Equiduct is fully committed to working alongside the Spanish retail brokerage community to ensure that an ever-growing number of individual investors receive the best possible execution for their transactions in Spanish & European equities and ETF.

Enrique Martí, CEO, iBroker, said: “Our incorporation into Equiduct strengthens iBroker’s commitment to providing our clients with the highest quality execution when trading in European equity markets. For retail investors, ensuring transparency in execution is not just an added value but an essential obligation. Thanks to Equiduct, we now have advanced tools that enable us to meet this premise in an exceptional way.

We are excited about this new chapter, where we aim to position iBroker Global Markets not only as the benchmark for Spanish investors specializing in derivatives but also as a prominent option for a new profile of retail investors interested in equities, ETFs, and savings and investment products.”

Wail Azizi, Chief Strategy Officer at Equiduct said: “I’d like to congratulate and welcome Enrique, Jon and the wider iBroker team to our exchange. We are delighted to be their chosen partner for expanding their retail business into European equities and ETFs. By delivering Best Execution on Europe’s most popular names and cost-effective high-quality data, we enable iBroker to offer unparalleled value to their retail investors.

iBroker’s success in the derivatives market demonstrates their leadership in making financial markets accessible to retail investors. Their strong commitment to financial education aligns seamlessly with Equiduct’s mission to promote and empower retail investment. This partnership reflects our shared dedication to driving positive change in pan-European trading for retail investors.”

Notes to editors

About Equiduct
Equiduct is an innovative, client driven pan-European exchange enabling retail brokers and institutional clients to achieve Best Execution in the most fragmented stocks and ETFs across 12 markets covering 16 European headline indices. Equiduct is a market segment of Börse Berlin, a regulated market operator under Article 44 of MiFID II. Börse Berlin is regulated by the Competent Authority Senatsverwaltung für Wirtschaft, Energie und Betriebe – Börsenaufsichtsbehörde and participation in trading is governed by German and European law. In 2023 it reported a turnover of €79bn and an overall ADV (average daily volume) of €310m.

About iBroker
iBroker Global Markets Sociedad de Valores is a leading Spanish online broker specializing in derivatives for retail investors. It provides brokerage services for futures and options on major international markets such as CME Group and EUREX, as well as OTC derivatives including CFDs and Forex.

The firm offers advanced trading platforms, developed in-house with a strong emphasis on technology. Its mission is to deliver an intuitive, secure, and efficient investment experience across both web and mobile platforms, with seamless integration options for leading solutions like TradingView and Visual Chart.

Through its recent agreement with Equiduct, iBroker has expanded its financial product offering to include European stocks and ETFs. The company plans to continue adding new products throughout 2025, reaffirming its commitment to innovation and diversification.

View original content:https://www.prnewswire.com/news-releases/equiduct-welcomes-ibroker-as-the-latest-trading-participant-to-join-apex-302324073.html

SOURCE Equiduct

Continue Reading

Trending